全文获取类型
收费全文 | 80801篇 |
免费 | 6378篇 |
国内免费 | 365篇 |
专业分类
耳鼻咽喉 | 773篇 |
儿科学 | 2076篇 |
妇产科学 | 1859篇 |
基础医学 | 10480篇 |
口腔科学 | 1905篇 |
临床医学 | 8466篇 |
内科学 | 18070篇 |
皮肤病学 | 1230篇 |
神经病学 | 6420篇 |
特种医学 | 2379篇 |
外国民族医学 | 2篇 |
外科学 | 12729篇 |
综合类 | 1411篇 |
现状与发展 | 1篇 |
一般理论 | 113篇 |
预防医学 | 6788篇 |
眼科学 | 2102篇 |
药学 | 5630篇 |
中国医学 | 149篇 |
肿瘤学 | 4961篇 |
出版年
2022年 | 530篇 |
2021年 | 1371篇 |
2020年 | 890篇 |
2019年 | 1263篇 |
2018年 | 1482篇 |
2017年 | 1076篇 |
2016年 | 1214篇 |
2015年 | 1403篇 |
2014年 | 2146篇 |
2013年 | 3334篇 |
2012年 | 4627篇 |
2011年 | 4909篇 |
2010年 | 2770篇 |
2009年 | 2625篇 |
2008年 | 4741篇 |
2007年 | 4967篇 |
2006年 | 4788篇 |
2005年 | 4896篇 |
2004年 | 4569篇 |
2003年 | 4153篇 |
2002年 | 4053篇 |
2001年 | 1284篇 |
2000年 | 1284篇 |
1999年 | 1244篇 |
1998年 | 964篇 |
1997年 | 813篇 |
1996年 | 687篇 |
1995年 | 649篇 |
1994年 | 621篇 |
1993年 | 605篇 |
1992年 | 1016篇 |
1991年 | 971篇 |
1990年 | 816篇 |
1989年 | 835篇 |
1988年 | 784篇 |
1987年 | 738篇 |
1986年 | 710篇 |
1985年 | 741篇 |
1984年 | 746篇 |
1983年 | 616篇 |
1982年 | 665篇 |
1981年 | 582篇 |
1980年 | 615篇 |
1979年 | 559篇 |
1978年 | 480篇 |
1977年 | 445篇 |
1976年 | 397篇 |
1975年 | 401篇 |
1974年 | 406篇 |
1973年 | 371篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Objective
The aim of the study was to estimate the effect of the state-based reinsurance programs through the section 1332 State Innovation Waivers on health insurance marketplace premiums and insurer participation.Data Source
2015 to 2022 Robert Wood Johnson Foundation Health Insurance Exchange Compare Datasets.Study Design
An event study difference-in-differences (DD) model separately for each year of implementation and a synthetic control method (SCM) are used to estimate year-by-year effects following program implementation.Data Collection/Extraction Methods
Not applicable.Principal Findings
Reinsurance programs were associated with a decline in premiums in the first year of implementation by 10%–13%, 5%–19%, and 11%–17% for bronze, silver, and gold plans (p < 0.05). There is a trend of sustained declines especially for states that implemented their programs in 2019 and 2020. The SCM analyses suggest some effect heterogeneity across states but also premium declines across most states. There is no evidence that reinsurance programs affected insurer participation.Conclusion
State-based reinsurance programs have the potential to improve the affordability of health insurance coverage. However, reinsurance programs do not appear to have had an effect on insurer participation, highlighting the need for policy makers to consider complementary strategies to encourage insurer participation. 相似文献2.
Rajendrababu Sharmila Puthuran George Varghese Alia Laxmi Ananya Uduman Mohammed Sithiq Wijesinghe Hiruni Kaushalya 《International ophthalmology》2022,42(8):2609-2618
International Ophthalmology - To investigate the efficacy and safety of non-valved Aurolab aqueous drainage implant (AADI) surgery combined with phacoemulsification in eyes with refractory glaucoma... 相似文献
3.
4.
5.
6.
Weiyu Ye Anna Olsson-Brown Robert A. Watson Vincent T. F. Cheung Robert D. Morgan Isar Nassiri Rosalin Cooper Chelsea A. Taylor Umair Akbani Oliver Brain Rubeta N. Matin Nicholas Coupe Mark R. Middleton Mark Coles Joseph J. Sacco Miranda J. Payne Benjamin P. Fairfax 《British journal of cancer》2021,124(10):1661
Background Immune checkpoint blockers (ICBs) activate CD8+ T cells, eliciting both anti-cancer activity and immune-related adverse events (irAEs). The relationship of irAEs with baseline parameters and clinical outcome is unclear.Methods Retrospective evaluation of irAEs on survival was performed across primary (N = 144) and secondary (N = 211) independent cohorts of patients with metastatic melanoma receiving single agent (pembrolizumab/nivolumab—sICB) or combination (nivolumab and ipilimumab—cICB) checkpoint blockade. RNA from pre-treatment and post-treatment CD8+ T cells was sequenced and differential gene expression according to irAE development assessed.Results 58.3% of patients developed early irAEs and this was associated with longer progression-free (PFS) and overall survival (OS) across both cohorts (log-rank test, OS: P < 0.0001). Median survival for patients without irAEs was 16.6 months (95% CI: 10.9–33.4) versus not-reached (P = 2.8 × 10−6). Pre-treatment monocyte and neutrophil counts, but not BMI, were additional predictors of clinical outcome. Differential expression of numerous gene pathway members was observed in CD8+ T cells according to irAE development, and patients not developing irAEs demonstrating upregulated CXCR1 pre- and post-treatment.Conclusions Early irAE development post-ICB is associated with favourable survival in MM. Development of irAEs is coupled to expression of numerous gene pathways, suggesting irAE development in-part reflects baseline immune activation.Subject terms: Immunotherapy, Melanoma 相似文献
7.
8.
9.
Turnbull Chris D. Stockley James A. Madathil Shyam Huq Syed S. A. Cooper Brendan G. Ali Asad Wharton Simon Stradling John R. Heitmar Rebekka 《Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie》2022,260(7):2129-2139
Graefe's Archive for Clinical and Experimental Ophthalmology - Retinal microvascular endothelial dysfunction is thought to be of importance in the development of ocular vascular diseases.... 相似文献